CA-GRINDR
11.7.2024 15:01:29 CEST | Business Wire | Press release
Grindr Inc. (NYSE:GRND), the premier LGBTQ+ social connector, today announced it has partnered with several organizations to launch in-app access to sexual health and safety resources for its users in 30 countries around the world. This wide-reaching program is led by Grindr for Equality, the company’s social impact initiative. Grindr users across 30 countries, including Brazil, Kenya, Spain, and Namibia, are now able to access these vital sexual health and safety resources directly through a side drawer on the Grindr app’s home screen, gaining localized and real-time information on the issues that matter to them the most.
Since 2015, Grindr for Equality has worked towards a world where the lives of Grindr users and the global LGBTQ+ community are free, equal, and just, advancing initiatives that impact communities on issues such as safety and sexual health. Lack of access to HIV testing is one of the biggest obstacles in the fight against the global HIV epidemic, posing a particular burden for some Grindr users, such as those living in rural areas or those who are not “out” to their families. Additionally, anti-LGBTQ+ legislation threatens the safety of members of the queer community every day by criminalizing their fundamental identities. With its new partnerships and its ongoing work, Grindr for Equality aims to empower users with real-time access to critical information that helps combat this adversity.
The new safety and sexual health resources available on the Grindr platform are led by Grindr for Equality’s partnership with European Test Finder, a free online tool that helps users find nearby locations for testing and treatment of HIV, Tuberculosis, Hepatitis B and C, and other STIs across the WHO European region. Grindr users across 24 countries supported by European Test Finder, including Austria, Belgium, Cyprus, France, Serbia, Slovakia, and Ukraine, are now able to quickly access vital public health services directly on Grindr. Grindr for Equality is also partnering with Ceska spolecnost aids pomoc, IntraHealth Namibia, IVOR Foundation, and The Love Tank to make additional sexual and mental health resources available to Grindr users in Czechia, Namibia, Bulgaria, and the United Kingdom, respectively.
In Brazil, Grindr for Equality is partnering with Ministério da Saúde, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis to provide in-app access to Onde encontrar a PrEP, a PrEP service locator. Grindr for Equality is also partnering with GALCK+ to provide Grindr users in Kenya with in-app access to Know Your Rights, a safety page designed to empower the Kenyan LGBQ community by informing them of their rights.
“Grindr is proud to partner with groups like CHIP and the EuroTEST Initiative that are hosting the European Test Finder to increase access to essential sexual health and safety resources for users around the world,” said Steph Niaupari of Grindr for Equality. “We’ve seen how in-app resources can help drive meaningful public health outcomes for the LGBTQ+ community, and we look forward to expanding the impact Grindr is able to achieve by providing a wider range of sexual health and safety resources to more of our global users.”
“We are thrilled to partner with Grindr to widen access to crucial testing and treatment for life-altering conditions such as HIV, Tuberculosis, and Hepatitis,” said Cæcilie Bom Kahama, project coordinator for the European Test Finder, at the secretariat of the EuroTEST Initiative, at CHIP in Denmark. “By helping more individuals quickly and easily access these public health services, Grindr is taking concrete steps to promote early diagnosis and care. We are grateful for the company’s leadership on this matter and hope this will encourage more people to test regularly and ultimately help reduce overall transmission.”
Today’s announcement builds on the success of Grindr for Equality’s existing partnerships to distribute free at-home HIV test kits directly to Grindr users across a growing list of countries including Georgia, Ireland, New Zealand, and the United States, as well as the City of London. In partnership with organizations including Building Healthy Online Communities, these programs have distributed more than 440,000 test kits to date. Grindr for Equality plans to launch similar initiatives and bring additional safety, sexual health, and advocacy resources to more Grindr users and members of the LGBTQ+ community around the world.
About Grindr Inc.
With more than 13.7 million monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015 Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711785938/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom